A biotechnology company targeting obesity and related metabolic conditions has made a move toward listing on U.S. public markets. Kalohexis, which focuses on clinical-stage drug development, submitted a confidential filing on Tuesday for an initial public offering, contributing to a growing surge of activity in the IPO space.
The company has not yet disclosed the financial terms of its planned offering.
Here is what is known about Kalohexis and its work:
The company was spun out of Endevica Bio in March and is led by the same leadership team that ran Endevica Bio. Its mission is to push forward the clinical development of its portfolio of drug candidates.
Kalohexis is working to treat metabolic disorders by focusing on the body’s melanocortin system — a natural mechanism that helps regulate metabolic balance. The company is building a pipeline of specialized peptides designed to safely interact with these key regulatory receptors in the body.
Its primary drug candidate, known as 710GO, is taken orally and is designed to activate both MC3 and MC4 receptors. The goal is to produce lasting weight loss in people living with general obesity.
The company is also developing a drug called mifomelatide, which works differently by blocking MC3R and MC4R receptors. This treatment is aimed at combating cachexia — a dangerous and potentially life-threatening wasting condition that can affect patients battling advanced cancers.
